

Intrahepatic Cholestasis Following Abuse of Powdered

Journal of Medical Toxicology

7, 227-231

DOI: [10.1007/s13181-011-0155-5](https://doi.org/10.1007/s13181-011-0155-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Natural product "legal highs"™. Natural Product Reports, 2012, 29, 1304.	5.2	30
2	Forensic analysis of mesembrine alkaloids in <i>Sceletium tortuosum</i> by nonaqueous capillary electrophoresis mass spectrometry. Electrophoresis, 2012, 33, 1567-1570.	1.3	30
3	Here Today, Gone Tomorrow and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. Journal of Medical Toxicology, 2012, 8, 15-32.	0.8	299
4	From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction. Neuroscience and Biobehavioral Reviews, 2013, 37, 138-151.	2.9	275
5	Natural Product (Fungal and Herbal) Novel Psychoactive Substances. , 2013, , 345-362.		8
6	Tryptamines. , 2013, , 363-381.		11
7	In vitro evaluation of cytochrome P450 induction and the inhibition potential of mitragynine, a stimulant alkaloid. Toxicology in Vitro, 2013, 27, 812-824.	1.1	25
8	Subchronic exposure to mitragynine, the principal alkaloid of <i>Mitragyna speciosa</i> , in rats. Journal of Ethnopharmacology, 2013, 146, 815-823.	2.0	64
9	Hazards Associated with the Use of Herbal and Other Natural Products. , 2013, , 335-356.		8
10	Unexpected Reduction of Indole Double Bond in Mitragynine Using <i>n</i> -Butylsilane and Catalytic Tris(pentafluorophenyl)borane. Synthetic Communications, 2014, 44, 1291-1295.	1.1	7
11	Kratom (<i>Mitragyna speciosa</i>) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 2014, 139, 132-137.	1.6	194
12	The Kratom Experience from Firsthand Reports. , 2014, , 230-261.		0
13	Cholestatic hepatitis from prolonged kratom use: A case report. Hepatology, 2015, 61, 1086-1087.	3.6	54
14	Screening and Identification of Mitragynine and 7-Hydroxymitragynine in Human Urine by LC-MS/MS. Chromatography (Basel), 2015, 2, 253-264.	1.2	9
15	Pharmacokinetics of mitragynine in man. Drug Design, Development and Therapy, 2015, 9, 2421.	2.0	62
16	Following "the Roots" of Kratom (<i>Mitragyna speciosa</i>): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. BioMed Research International, 2015, 2015, 1-11.	0.9	149
17	Herbal Supplements and Hepatotoxicity: A Short Review. Natural Product Communications, 2015, 10, 1934578X1501001.	0.2	7
18	Social Functioning of Kratom (<i>Mitragyna speciosa</i>) Users in Malaysia. Journal of Psychoactive Drugs, 2015, 47, 125-131.	1.0	76

#	ARTICLE	IF	CITATIONS
19	Experiences of Kratom Users: A Qualitative Analysis. <i>Journal of Psychoactive Drugs</i> , 2015, 47, 360-367.	1.0	110
20	New Drugs of Abuse. <i>Pharmacotherapy</i> , 2015, 35, 189-197.	1.2	61
21	Hepatotoxicity Induced by <i>œthe 3Ks</i> Kava, Kratom and Khat. <i>International Journal of Molecular Sciences</i> , 2016, 17, 580.	1.8	79
22	Update on the Pharmacology and Legal Status of Kratom. <i>Journal of Osteopathic Medicine</i> , 2016, 116, 802-809.	0.4	43
23	Kratom (<i>Mitragyna speciosa</i>) Use, Addiction Potential, and Legal Status. , 2016, , 903-911.		4
24	Neurobiology of Kratom and its main alkaloid mitragynine. <i>Brain Research Bulletin</i> , 2016, 126, 29-40.	1.4	75
25	Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. <i>Brain Research Bulletin</i> , 2016, 126, 41-46.	1.4	151
26	Abuse potential and adverse cognitive effects of mitragynine (kratom). <i>Addiction Biology</i> , 2016, 21, 98-110.	1.4	104
27	Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine. <i>Journal of Medical Toxicology</i> , 2016, 12, 341-349.	0.8	93
28	Mitragynine and its potential blocking effects on specific cardiac potassium channels. <i>Toxicology and Applied Pharmacology</i> , 2016, 305, 22-39.	1.3	16
29	Chemical characterization and in vitro cyto- and genotoxicity of <i>œlegal high</i> ™ products containing Kratom (<i>Mitragyna speciosa</i>). <i>Forensic Toxicology</i> , 2016, 34, 213-226.	1.4	9
30	The pharmacology and toxicology of kratom: from traditional herb to drug of abuse. <i>International Journal of Legal Medicine</i> , 2016, 130, 127-138.	1.2	150
31	Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. <i>Drug and Alcohol Dependence</i> , 2017, 180, 340-348.	1.6	96
32	The Harm in Kratom. <i>Oncologist</i> , 2017, 22, 1010-1011.	1.9	10
33	<i>Mitragyna speciosa</i> : Balancing Potential Medical Benefits and Abuse. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 897-899.	1.3	13
34	Current Opiate and Opioid Hazards in Children and Adolescents. <i>Clinical Pediatric Emergency Medicine</i> , 2017, 18, 173-180.	0.4	3
35	Biochemical Benefits, Diagnosis, and Clinical Risks Evaluation of Kratom. <i>Frontiers in Psychiatry</i> , 2017, 8, 62.	1.3	49
36	The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. <i>Psychopharmacology</i> , 2018, 235, 573-589.	1.5	102

#	ARTICLE	IF	CITATIONS
37	Evaluating the hematological and clinical-chemistry parameters of kratom (<i>Mitragyna speciosa</i>) users in Malaysia. <i>Journal of Ethnopharmacology</i> , 2018, 214, 197-206.	2.0	49
38	Recurrent seizures from chronic kratom use, an atypical herbal opioid. <i>Epilepsy & Behavior Case Reports</i> , 2018, 10, 18-20.	1.5	28
39	Severity of Pain and Sleep Problems during Kratom (<i>Mitragyna speciosa</i> Korth.) Cessation among Regular Kratom Users. <i>Journal of Psychoactive Drugs</i> , 2018, 50, 266-274.	1.0	25
40	Kratom, an Emerging Drug of Abuse, Raises Prolactin and Causes Secondary Hypogonadism: Case Report. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961876502.	0.3	14
41	Clinical outcomes after Kratom exposures: A poison center case series. <i>American Journal of Emergency Medicine</i> , 2018, 36, 166-168.	0.7	31
42	Kratom, an Emerging Drug of Abuse: A Case Report of Overdose and Management of Withdrawal. <i>A&A Practice</i> , 2018, 10, 192-194.	0.2	33
43	Kratom use and mental health: A systematic review. <i>Drug and Alcohol Dependence</i> , 2018, 183, 134-140.	1.6	104
44	MITRAGYNA SPECIOSA-INDUCED HEPATOTOXICITY-TREATED EFFECTIVELY BY PIPER BETLE: SCOPE AS A FUTURE ANTIDOTE. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 2018, 11, 43.	0.3	2
45	Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity. <i>Journal of Medical Toxicology</i> , 2018, 14, 306-322.	0.8	56
46	Possible kratom-induced hepatomegaly: A case report. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 561-563.	0.7	19
47	A review on the abuse of three NPS (synthetic cannabinoids, kratom, poppers) among youths in Asia. <i>Forensic Science International</i> , 2018, 292, 45-49.	1.3	18
48	Histologic Characterization of Kratom Use-Associated Liver Injury. <i>Gastroenterology Research</i> , 2018, 11, 79-82.	0.4	24
49	Kratom: a dangerous player in the opioid crisis. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2018, 8, 107-110.	0.4	30
50	The Trouble With Kratom: Analytical and Interpretative Issues Involving Mitragynine. <i>Journal of Analytical Toxicology</i> , 2019, 43, 615-629.	1.7	29
51	Characteristics of deaths associated with kratom use. <i>Journal of Psychopharmacology</i> , 2019, 33, 1102-1123.	2.0	67
52	&p>Current perspectives on the impact of Kratom use</p>. <i>Substance Abuse and Rehabilitation</i> , 2019, Volume 10, 23-31.	1.6	98
53	Why Does the Food and Drug Administration Need to Ban Kratom?. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 169-174.	0.6	1
54	Cardiac arrest in a young healthy male patient secondary to kratom ingestion: is this 'legal high' substance more dangerous than initially thought ?. <i>BMJ Case Reports</i> , 2019, 12, e229778.	0.2	15

#	ARTICLE	IF	CITATIONS
55	Kratom from Head to Toe—Case Reviews of Adverse Events and Toxicities. <i>Current Emergency and Hospital Medicine Reports</i> , 2019, 7, 141-168.	0.6	24
56	Novel Drugs of Abuse. <i>Pediatrics in Review</i> , 2019, 40, 71-78.	0.2	5
57	Kratom policy: The challenge of balancing therapeutic potential with public safety. <i>International Journal of Drug Policy</i> , 2019, 70, 70-77.	1.6	83
58	Self-reported prevalence and severity of opioid and kratom (<i>Mitragyna speciosa</i> korth.) side effects. <i>Journal of Ethnopharmacology</i> , 2019, 238, 111876.	2.0	40
59	<i>Mitragyna speciosa</i> : Clinical, Toxicological Aspects and Analysis in Biological and Non-Biological Samples. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 35.	0.7	39
60	Kratom-Induced Cholestatic Liver Injury and Its Conservative Management. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019, 7, 232470961983613.	0.3	19
61	Drug-Induced Liver Injury Caused by Kratom Use as an Alternative Pain Treatment Amid an Ongoing Opioid Epidemic. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2019, 7, 232470961982616.	0.3	26
62	Kratom exposures reported to United States poison control centers: 2011–2017. <i>Clinical Toxicology</i> , 2019, 57, 847-854.	0.8	105
63	Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells. <i>Scientific Reports</i> , 2019, 9, 19757.	1.6	11
64	Herb-Induced Liver Injury With Cholestasis and Renal Injury Secondary to Short-Term Use of Kratom (<i>Mitragyna speciosa</i>). <i>American Journal of Therapeutics</i> , 2019, 26, e546-e547.	0.5	22
65	Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of <i>Mitragyna speciosa</i> (kratom). <i>Xenobiotica</i> , 2019, 49, 1279-1288.	0.5	70
66	The inhibitory effects of mitragynine on P-glycoprotein in vitro. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2019, 392, 481-496.	1.4	23
67	Motives for using Kratom (<i>Mitragyna speciosa</i> Korth.) among regular users in Malaysia. <i>Journal of Ethnopharmacology</i> , 2019, 233, 34-40.	2.0	41
68	Non-Medical Use of Novel Synthetic Opioids: A New Challenge to Public Health. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 177.	1.2	39
69	Constipation prevalence and fatigue severity in regular kratom (<i>Mitragyna speciosa</i> Korth.) users. <i>Journal of Substance Use</i> , 2019, 24, 233-239.	0.3	5
70	Improved sexual functioning of long-term daily users of <i>Mitragyna speciosa</i> (Korth.). <i>Journal of Herbal Medicine</i> , 2020, 19, 100293.	1.0	6
71	Detection and Identification of Kratom (<i>Mitragyna speciosa</i>) and Marijuana (<i>Cannabis sativa</i>) by a Real-Time Polymerase Chain Reaction High-Resolution Melt Duplex Assay. <i>Journal of Forensic Sciences</i> , 2020, 65, 52-60.	0.9	7
72	Kratom (<i>Mitragyna Speciosa</i>) Liver Injury: A Comprehensive Review. <i>Drugs</i> , 2020, 80, 263-283.	4.9	41

#	ARTICLE	IF	CITATIONS
73	Identification of metabolites and potential biomarkers of kratom in urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1140, 121971.	1.2	9
74	Case series: Mitragynine blood and tissue concentrations in fatalities from 2017 to 2018 in Orange County, CA, USA. <i>Forensic Chemistry</i> , 2020, 17, 100205.	1.7	6
75	A Complex Case of Kratom Dependence, Depression, and Chronic Pain in Opioid Use Disorder: Effects of Buprenorphine in Clinical Management. <i>Journal of Psychoactive Drugs</i> , 2020, 52, 447-452.	1.0	23
76	Lipid profile of regular kratom (<i>Mitragyna speciosa</i> Korth.) users in the community setting. <i>PLoS ONE</i> , 2020, 15, e0234639.	1.1	12
77	Kratom—Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review. <i>Pain and Therapy</i> , 2020, 9, 55-69.	1.5	90
78	The Right to Use Kratom from the Psychiatric and Islamic Perspectives. <i>Journal of Religion and Health</i> , 2021, 60, 841-853.	0.8	0
79	A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 74-83.	1.1	20
80	Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. <i>Frontiers in Psychiatry</i> , 2021, 12, 640218.	1.3	13
81	Intracerebral hemorrhage after kratom ingestion. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2021, 34, 33-36.	0.1	4
82	Kratom: A systematic review of toxicological issues. <i>Wiley Interdisciplinary Reviews Forensic Science</i> , 2022, 4, .	1.2	7
83	Kratom-induced transaminitis with subsequent precipitated opioid withdrawal following naltrexone. <i>Mental Health Clinician</i> , 2021, 11, 220-224.	0.5	7
84	New Designer Drugs. <i>Emergency Medicine Clinics of North America</i> , 2021, 39, 677-687.	0.5	3
85	Herb-induced liver injury: Systematic review and meta-analysis. <i>World Journal of Clinical Cases</i> , 2021, 9, 5490-5513.	0.3	33
86	Mitragynine (Kratom)-Induced Cognitive Impairments in Mice Resemble Δ^9 -THC and Morphine Effects: Reversal by Cannabinoid CB1 Receptor Antagonism. <i>Frontiers in Pharmacology</i> , 2021, 12, 708055.	1.6	11
87	Tryptamines. , 2022, , 495-532.		0
88	Effect of Subacute Dose of <i>Mitragyna Speciosa</i> Korth Crude Extract in Female Sprague Dawley Rats. <i>Journal of Medical and Bioengineering</i> , 2014, 3, 98-101.	0.5	4
89	Kratom-Induced Cholestatic Liver Injury Mimicking Anti-Mitochondrial Antibody-Negative Primary Biliary Cholangitis: A Case Report and Review of Literature. <i>Gastroenterology Research</i> , 2019, 12, 211-215.	0.4	20
90	Kratom Dependence and Treatment Options: A Comprehensive Review of the Literature. <i>Current Drug Targets</i> , 2020, 21, 1566-1579.	1.0	14

#	ARTICLE	IF	CITATIONS
91	Substance Use Disorder Related to Kratom (<i>Mitragyna speciosa</i>) Use in Malaysia. <i>Current Psychopharmacology</i> , 2019, 8, 64-71.	0.1	10
92	Kratom induced severe cholestatic liver injury histologically mimicking primary biliary cholangitis: A case report. <i>World Journal of Hepatology</i> , 2020, 12, 863-869.	0.8	7
93	Psychoactive natural products: overview of recent developments. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2014, 50, 12-27.	0.2	31
94	Undifferentiated Shock and Extreme Elevation of Procalcitonin Related to Kratom Use. <i>Indian Journal of Critical Care Medicine</i> , 2019, 23, 239-241.	0.3	9
96	Kratom, a novel herbal opioid in a patient with benzodiazepine use disorder. , 2020, , 373-377.		0
97	The effect of mitragynine on extracellular activity of brain dopamine and its metabolites. <i>Brain Research Bulletin</i> , 2022, 178, 1-8.	1.4	2
98	Comparison of biochemical and safety parameters of regular kratom (<i>Mitragyna speciosa</i>) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 5	0.3	1
99	<i>Mitragyna</i> Species as Pharmacological Agents: From Abuse to Promising Pharmaceutical Products. <i>Life</i> , 2022, 12, 193.	1.1	8
100	Acute liver injury following short-term use of the herbal supplement kratom. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2022, 35, 39-41.	0.1	2
102	Understanding Kratom Use: A Guide for Healthcare Providers. <i>Frontiers in Pharmacology</i> , 2022, 13, 801855.	1.6	30
103	Kratom (<i>Mitragyna speciosa</i>)-Induced Hepatitis. <i>ACG Case Reports Journal</i> , 2022, 9, e00715.	0.2	2
105	Kratom exposures managed by the British Columbia poison centre, 2012â€“2019: a descriptive analysis. <i>CMAJ Open</i> , 2022, 10, E755-E761.	1.1	1
106	Hepatotoxicity due to herbal dietary supplements: Past, present and the future. <i>Food and Chemical Toxicology</i> , 2022, 169, 113445.	1.8	9
107	Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1819-1830.	0.9	0
108	Controversial usages of kratom (<i>Mitragyna speciosa</i>): For good or for evil. <i>World Journal of Pharmacology</i> , 0, 11, 16-26.	1.3	0
109	Patterns of polysubstance use among adults in Malaysiaâ€”A latent class analysis. <i>PLoS ONE</i> , 2023, 18, e0264593.	1.1	1
110	Omissions, Ambiguities, and Underuse of Causal Assessment Tools: a Systematic Review of Case Reports on Patients Who Use Kratom. <i>Current Addiction Reports</i> , 2023, 10, 293-303.	1.6	5